The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     
 


Published online June 24, 2009
The Journal of Immunology, 2009, doi:10.4049/jimmunol.0804000
Copyright © 2009 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jimmunol.0804000v1
183/2/1435    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Yang, Y. H.
Right arrow Articles by Morand, E. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, Y. H.
Right arrow Articles by Morand, E. F.

Annexin-1 Regulates Macrophage IL-6 and TNF via Glucocorticoid-Induced Leucine Zipper1

Yuan H. Yang2, Daniel Aeberli, April Dacumos, Jin R. Xue and Eric F. Morand

Centre for Inflammatory Diseases, Department of Medicine, Monash University, Clayton, Victoria, Australia

Annexin-1 (ANXA1) is a mediator of the anti-inflammatory actions of endogenous and exogenous glucocorticoids (GC). The mechanism of ANXA1 effects on cytokine production in macrophages is unknown and is here investigated in vivo and in vitro. In response to LPS administration, ANXA1–/– mice exhibited significantly increased serum IL-6 and TNF compared with wild-type (WT) controls. Similarly, LPS-induced IL-6 and TNF were significantly greater in ANXA1–/– than in WT peritoneal macrophages in vitro. In addition, deficiency of ANXA1 was associated with impairment of the inhibitory effects of dexamethasone (DEX) on LPS-induced IL-6 and TNF in macrophages. Increased LPS-induced cytokine expression in the absence of ANXA1 was accompanied by significantly increased LPS-induced activation of ERK and JNK MAPK and was abrogated by inhibition of either of these pathways. No differences in GC effects on MAPK or MAPK phosphatase 1 were observed in ANXA1–/– cells. In contrast, GC-induced expression of the regulatory protein GILZ was significantly reduced in ANXA1–/– cells by silencing of ANXA1 in WT cells and in macrophages of ANXA1–/– mice in vivo. GC-induced GILZ expression and GC inhibition of NF-{kappa}B activation were restored by expression of ANXA1 in ANXA1–/– cells, and GILZ overexpression in ANXA1–/– macrophages reduced ERK MAPK phosphorylation and restored sensitivity of cytokine expression and NF-{kappa}B activation to GC. These data confirm ANXA1 as a key inhibitor of macrophage cytokine expression and identify GILZ as a previously unrecognized mechanism of the anti-inflammatory effects of ANXA1.

2 Address correspondence and reprint requests to Dr. Yuan H. Yang, Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Locked Bag 29 Clayton, Victoria 3168, Australia. E-mail address: yuan.yang{at}med.monash.edu.au

1 This work was supported by the National Health and Medical Research Council, Australia. D. A. was supported by grants from Novartis and the Swiss Foundation for Research in Medicine and Biology.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.